These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 10399376

  • 1. [The concomitant presence of prohemorrhagic and thrombophilic changes in coagulation factor V: a severe defect of coagulant activity and homozygote resistance to activated protein C].
    Rossi V, Di Rocco N, Del Sonno C, Crivelli S.
    Ann Ital Med Int; 1999; 14(2):127-9. PubMed ID: 10399376
    [Abstract] [Full Text] [Related]

  • 2. [Activated protein C resistance--a recently discovered hereditary thrombophilia].
    Moland L, Sandset PM.
    Tidsskr Nor Laegeforen; 1998 Sep 30; 118(23):3590-5. PubMed ID: 9820002
    [Abstract] [Full Text] [Related]

  • 3. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
    Papaian LP, Kobilianskaia VA, Sheĭdina AM, Baranovskaia SS, Sirotkina OV, Kargin VD, Saltykova NB, Beliazo OE, Golovina OG, Papaian KA, Tarkovskaia LR.
    Ter Arkh; 2001 Sep 30; 73(7):47-51. PubMed ID: 11523408
    [Abstract] [Full Text] [Related]

  • 4. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE.
    Thromb Haemost; 2002 Feb 30; 87(2):199-205. PubMed ID: 11859850
    [Abstract] [Full Text] [Related]

  • 5. [Diagnosis of thrombophilia based on coagulation and genetic studies].
    Bałszan-Kowalska I.
    Ann Acad Med Stetin; 2002 Feb 30; 48():179-93. PubMed ID: 14601477
    [Abstract] [Full Text] [Related]

  • 6. Activated protein C (APC) resistance: considerations about the importance of using the original and modified methods in thrombophilic disease.
    Gennari L, Blanco AN, Bermejo E, Salviú J, Grosso S, Lazzari MA.
    Thromb Haemost; 2000 Jul 30; 84(1):138-9. PubMed ID: 10928486
    [No Abstract] [Full Text] [Related]

  • 7. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
    Payzin B, Adakan FY, Yalçin HC, Cetinkaya GS, Berkmen S, Eraslan S, Unsal B.
    Turk J Gastroenterol; 2006 Sep 30; 17(3):183-90. PubMed ID: 16941251
    [Abstract] [Full Text] [Related]

  • 8. Thrombophilic markers in patients with congenital bleeding disorders.
    Vezendi K, Tápai K, Erdödi E, Szabó I, Tomek A, Oszlács J, Scheibl E.
    Haematologia (Budap); 2002 Sep 30; 32(4):467-73. PubMed ID: 12803120
    [Abstract] [Full Text] [Related]

  • 9. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.
    Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM.
    Thromb Haemost; 2001 Sep 30; 86(3):800-3. PubMed ID: 11583310
    [Abstract] [Full Text] [Related]

  • 10. In the presence of other inherited or acquired high-risk situations, the FV Cambridge mutation may be an additional thrombophilic risk factor, through its effect on APC sensitivity.
    Santacroce R, Bossone A, Brancaccio V, Fortina P, Margaglione M.
    Thromb Haemost; 2000 Jun 30; 83(6):963-4. PubMed ID: 10896257
    [No Abstract] [Full Text] [Related]

  • 11. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance.
    Mikovic D, Rakicevic L, Kovac M, Radojkovic D.
    Thromb Haemost; 2000 Oct 30; 84(4):723-4. PubMed ID: 11057877
    [No Abstract] [Full Text] [Related]

  • 12. [National evaluation of the diagnosis of activated protein C resistance].
    Montiel-Manzano G, de la Peña-Díaz A, Majluf-Cruz A, Cesarman-Maus G, Corona-de la Peña N, Cruz-Cruz D, Gaminio E, Martínez-Murillo C, Mayagoitia T, Miranda-Peralta E, Poblete T, Quintana-Martínez S, Ramírez R, Razo D, Ruiz de Chávez-Ochoa A, Reyes-Núñez VA, Salazar R, Vicencio-Santiago GV, Villa R.
    Rev Invest Clin; 2003 Oct 30; 55(3):358-69. PubMed ID: 14515684
    [Abstract] [Full Text] [Related]

  • 13. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G, Valverde S.
    Blood Coagul Fibrinolysis; 2007 Oct 30; 18(7):603-10. PubMed ID: 17890946
    [Abstract] [Full Text] [Related]

  • 14. Screening for inherited thrombophilia: indications and therapeutic implications.
    De Stefano V, Rossi E, Paciaroni K, Leone G.
    Haematologica; 2002 Oct 30; 87(10):1095-108. PubMed ID: 12368166
    [Abstract] [Full Text] [Related]

  • 15. Association of factor V deficiency with factor V HR2.
    Faioni EM, Castaman G, Asti D, Lussana F, Rodeghiero F.
    Haematologica; 2004 Feb 30; 89(2):195-200. PubMed ID: 15003895
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
    El-Karaksy H, El-Koofy N, El-Hawary M, Mostafa A, Aziz M, El-Shabrawi M, Mohsen NA, Kotb M, El-Raziky M, El-Sonoon MA, A-Kader H.
    Ann Hematol; 2004 Nov 30; 83(11):712-5. PubMed ID: 15309526
    [Abstract] [Full Text] [Related]

  • 17. Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening.
    Fábregues F, Tàssies D, Reverter JC, Carmona F, Ordinas A, Balasch J.
    Fertil Steril; 2004 Apr 30; 81(4):989-95. PubMed ID: 15066453
    [Abstract] [Full Text] [Related]

  • 18. [APC resistance--most frequent familial thrombophilia].
    Herren S, Lämmle B.
    Ther Umsch; 1999 Sep 30; 56(9):499-501. PubMed ID: 10517118
    [Abstract] [Full Text] [Related]

  • 19. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
    Rolla R, Vidali M, Meola S, Pollarolo P, Pergolini P, Bellomo G.
    Clin Lab; 2011 Sep 30; 57(9-10):711-7. PubMed ID: 22029186
    [Abstract] [Full Text] [Related]

  • 20. Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family.
    Santamaría A, Soria JM, Tirado I, Mateo J, Coll I, Souto JC, Fontcuberta J.
    Thromb Haemost; 2005 Jun 30; 93(6):1193-5. PubMed ID: 15968408
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.